Literature DB >> 23740237

The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab.

Ch Plasencia1, D Pascual-Salcedo, P Alcocer, M G Bonilla, A Villalba, D Peiteado, F Arribas, J Díez, M T Lopez-Casla, E Martín-Mola, A Balsa.   

Abstract

Entities:  

Keywords:  Anti-TNF; Rheumatoid Arthritis; Treatment

Mesh：

Substances：

Year:  2013        PMID： 23740237     DOI： 10.1136/annrheumdis-2013-203353

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  4 in total

1.  Monitoring drug and antidrug levels: a rational approach in rheumatoid arthritis patients treated with biologic agents who experience inadequate response while being on a stable biologic treatment.

Authors:  Diana Mazilu; Daniela Opriş; Cecilia Gainaru; Mihaela Iliuta; Natalia Apetrei; Giorgiana Luca; Andreea Borangiu; Tania Gudu; Alexandra Peltea; Laura Groseanu; Cosmin Constantinescu; Ioana Saulescu; Violeta Bojinca; Andra Balanescu; Denisa Predeteanu; Ruxandra Ionescu
Journal:  Biomed Res Int       Date:  2014-05-20       Impact factor: 3.411

2.  Adalimumab concentration-based tapering strategy: as good as the recommended dosage.

Authors:  Denis Mulleman; Alejandro Balsa
Journal:  Ann Rheum Dis       Date:  2018-01-06       Impact factor: 19.103

Review 3.  Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases.

Authors:  Erwin Dreesen; Peter Bossuyt; Denis Mulleman; Ann Gils; Dora Pascual-Salcedo
Journal:  Clin Pharmacol       Date:  2017-10-03

Review 4.  Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far.

Authors:  Meghna Jani; William G Dixon; Hector Chinoy
Journal:  Rheumatology (Oxford)       Date:  2018-11-01       Impact factor: 7.580
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.